Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.
about
Data submission and quality in microarray-based microRNA profilingClinical significance of microRNAs in chronic and acute human leukemiaGenetics of myeloproliferative neoplasmsTherapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAsRole of HOXA9 in leukemia: dysregulation, cofactors and essential targetsPROGmiR: a tool for identifying prognostic miRNA biomarkers in multiple cancers using publicly available data.FAMLF is a target of miR-181b in Burkitt lymphoma.PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation.A 3-miRNA signature predicts prognosis of pediatric and adolescent cytogenetically normal acute myeloid leukemia.Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia.MicroRNAs in Cancer Biology and Therapy: Current Status and Perspectives.Prognostic role of microRNA-181a/b in hematological malignancies: a meta-analysisERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer.Increased expression of miR-24 is associated with acute myeloid leukemia with t(8;21).PBX3 promotes migration and invasion of colorectal cancer cells via activation of MAPK/ERK signaling pathway.MicroRNA-150 expression induces myeloid differentiation of human acute leukemia cells and normal hematopoietic progenitorsThe pathological role and prognostic impact of miR-181 in acute myeloid leukemiaThe 5' flanking region of miR-378 is hypomethylated in acute myeloid leukemiaLow expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia.PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.Two isoforms of HOXA9 function differently but work synergistically in human MLL-rearranged leukemia.Overexpression and knockout of miR-126 both promote leukemogenesisMicroRNA-181a enhances the chemotherapeutic sensitivity of chronic myeloid leukemia to imatinib.Gene expression profiling and candidate gene resequencing identifies pathways and mutations important for malignant transformation caused by leukemogenic fusion genes.MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.MicroRNA profiling in pediatric pilocytic astrocytoma reveals biologically relevant targets, including PBX3, NFIB, and METAP2.Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemiamiR-199b, a novel tumor suppressor miRNA in acute myeloid leukemia with prognostic implicationsThe cell fate determinant Llgl1 influences HSC fitness and prognosis in AML.MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid MalignanciesPBX3 is an important cofactor of HOXA9 in leukemogenesis.Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged DiseaseCritical role of miR-9 in myelopoiesis and EVI1-induced leukemogenesisTET1 plays an essential oncogenic role in MLL-rearranged leukemiaAn early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia studyExpression of microRNA-181 determines response to treatment with azacitidine and predicts survival in elderly patients with acute myeloid leukaemiaThe role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemiaMicroRNA-497 suppresses cell proliferation and induces apoptosis through targeting PBX3 in human multiple myeloma.Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia.
P2860
Q24282608-FEDA4593-CC7F-4CF9-84A1-DFF7C4F15EDDQ26749533-6225478E-419B-4D68-8008-6C49910786CDQ26823651-59AA32F9-0EDB-402A-A1C3-2A25437E7604Q28071427-517BC794-995E-4D73-B5B2-B15F90F8DB6DQ28082027-493C715B-8DB0-4A8D-ADBE-6D564C1F1DEDQ30583504-1507383D-D5E7-44BD-8F91-1984C88C5B51Q33718130-4DC6FA30-139E-4681-8D20-31AF18593548Q33767159-CD63A9FD-2006-45AB-A8E0-91C1CD1A87E1Q33889001-5F3AE2F4-AF37-4905-B4B6-A5F7C5287729Q34599349-7EA90082-E6A1-4B3B-80E5-88B6C621348BQ34599354-3E1E51FF-8AA1-4F17-A055-64EB434DDCECQ34637868-EB4DB4A8-DB63-453B-8568-F4919BBE85B0Q34652823-785F59EB-7EAF-4F43-BA67-11012EF02023Q34732919-AC76AB4D-DBBA-46CE-8B82-695966A0F5B8Q34779146-69AB7EE1-AC75-4A50-A239-A1DE4B25D522Q35006000-D9674A47-7952-450B-BF53-82FA2906B08CQ35738628-70F65F1F-6F4B-49E2-B0F9-DF0A6D259F7FQ35853830-2909C2A9-8D65-4659-ADFB-B63C4296EF78Q35857675-5D32F3E9-4273-4B84-B2F9-D4E724EC72B5Q35958274-4E5AB9DD-EAEC-4FDD-BD63-452F545ADF08Q36101066-E97B096F-87C7-4C11-9FFB-14487737C145Q36193187-3126B41B-0B26-482D-822C-370C0FC075E1Q36334277-DBC36F25-7B34-4F84-A37C-8A3084F624D2Q36392936-2B5FD968-6A59-4CA3-832A-CCE9B290269FQ36437006-60D8664E-1677-48CF-BBD7-6566A5169633Q36500392-400A30C5-DBA0-42AB-9E0B-2BF63B0C4FE3Q36512601-D6876B3F-83E4-4C1C-A6D3-73BAD65776FFQ36542965-B1B466D0-605A-44F6-902B-1492F7AB3012Q36547690-91B1C5ED-3141-41BD-AD61-329FCF5E25A1Q36602853-5084ECA2-93A2-4115-94D4-FFDC61C0EA2DQ36628305-26672F99-1B09-4907-B84A-17F2C35F9213Q36678141-31A6E2B6-F590-4F6C-8582-03FD7C40E4CFQ36735211-902834ED-5F53-462C-B842-362F374E41DEQ36747434-7FD5905A-18EF-4BC8-AB2D-FBA33255F239Q37031819-C9D8DF3A-11BF-4F05-931A-6ABAF5D489B0Q37237899-585836BB-B519-49C8-A4D7-B0A1B5FA5453Q37288474-D09214CF-E0D2-42F0-9FD7-0C46485C8B51Q37379386-27765556-AA1C-48F0-B580-A682C42B2CB5Q37545119-EC0123B1-DB76-4B41-BEBA-9D87E6B2808EQ37644854-14DE68A7-9E76-46D3-A6F2-9C00913FFC5A
P2860
Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Up-regulation of a HOXA-PBX3 h ...... cytogenetically abnormal AML.
@ast
Up-regulation of a HOXA-PBX3 h ...... cytogenetically abnormal AML.
@en
type
label
Up-regulation of a HOXA-PBX3 h ...... cytogenetically abnormal AML.
@ast
Up-regulation of a HOXA-PBX3 h ...... cytogenetically abnormal AML.
@en
prefLabel
Up-regulation of a HOXA-PBX3 h ...... cytogenetically abnormal AML.
@ast
Up-regulation of a HOXA-PBX3 h ...... cytogenetically abnormal AML.
@en
P2093
P2860
P50
P1433
P1476
Up-regulation of a HOXA-PBX3 h ...... cytogenetically abnormal AML.
@en
P2093
Abdel Elkahloun
Chunjiang He
Colles Price
Janet D Rowley
Jianjun Chen
Lars Bullinger
Mary Beth Neilly
Michael A Caligiuri
P2860
P304
P356
10.1182/BLOOD-2011-10-386235
P407
P577
2012-01-17T00:00:00Z